Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections

BACKGROUND: BCG is recommended as intravesical immunotherapy to reduce the risk of tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). Currently, it is unknown whether intravesical BCG application induces trained immunity. METHODS: The aim of this research was to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: van Puffelen, Jelmer H, Novakovic, Boris, van Emst, Liesbeth, Kooper, Denise, Zuiverloon, Tahlita C M, Oldenhof, Ursula T H, Witjes, J Alfred, Galesloot, Tessel E, Vrieling, Alina, Aben, Katja K H, Kiemeney, Lambertus A L M, Oosterwijk, Egbert, Netea, Mihai G, Boormans, Joost L, van der Heijden, Antoine G, Joosten, Leo A B, Vermeulen, Sita H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884868/
https://www.ncbi.nlm.nih.gov/pubmed/36693678
http://dx.doi.org/10.1136/jitc-2022-005518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884868/
https://www.ncbi.nlm.nih.gov/pubmed/36693678
http://dx.doi.org/10.1136/jitc-2022-005518

Ejemplares similares